Jardiance meets in pair of Phase III trials for Type I diabetes

Boehringer Ingelheim GmbH (Ingelheim, Germany) and Eli Lilly and Co. (NYSE:LLY) said once-daily oral Jardiance empagliflozin as an adjunct to insulin met the primary endpoint of reducing HbA1c from baseline to week 26 vs. placebo in both the Phase III EASE-2 and EASE-3 trials to treat Type I diabetes. The partners said they are discussing next steps and exploring regulatory options for Jardiance in the indication.

The sodium-glucose cotransporter 2 (SGLT2) inhibitor is approved in the U.S. and EU as an adjunct to diet and exercise to improve glycemic control in adults with Type II diabetes...